Novel variants of major drug-metabolising enzyme genes in diverse African populations and their predicted functional effects
- PMID: 19164093
- PMCID: PMC3525272
- DOI: 10.1186/1479-7364-3-2-169
Novel variants of major drug-metabolising enzyme genes in diverse African populations and their predicted functional effects
Abstract
Pharmacogenetics enables personalised therapy based on genetic profiling and is increasingly applied in drug discovery. Medicines are developed and used together with pharmacodiagnostic tools to achieve desired drug efficacy and safety margins. Genetic polymorphism of drug-metabolising enzymes such as cytochrome P450s (CYPs) and N-acetyltransferases (NATs) has been widely studied in Caucasian and Asian populations, yet studies on African variants have been less extensive. The aim of the present study was to search for novel variants of CYP2C9 , CYP2C19 , CYP2D6 and NAT2 genes in Africans, with a particular focus on their prevalence in different populations, their relevance to enzyme functionality and their potential for personalised therapy. Blood samples from various ethnic groups were obtained from the AiBST Biobank of African Populations. The nine exons and exon-intron junctions of the CYP genes and exon 2 of NAT2 were analysed by direct DNA sequencing. Computational tools were used for the identification, haplotype analysis and prediction of functional effects of novel single nucleotide polymorphisms (SNPs). Novel SNPs were discovered in all four genes, grouped to existing haplotypes or assigned new allele names, if possible. The functional effects of non-synonymous SNPs were predicted and known African-specific variants were confirmed, but no significant differences were found in the frequencies of SNPs between African ethnicities. The low prevalence of our novel variants and most known functional alleles is consistent with the generally high level of diversity in gene loci of African populations. This indicates that profiles of rare variants reflecting interindividual variability might become the most relevant pharmacodiagnostic tools explaining Africans' diversity in drug response.
Figures

Similar articles
-
Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population.Eur J Clin Pharmacol. 2003 Aug;59(4):303-12. doi: 10.1007/s00228-003-0606-2. Epub 2003 Jul 15. Eur J Clin Pharmacol. 2003. PMID: 12879168
-
Clinical pharmacogenetics and potential application in personalized medicine.Curr Drug Metab. 2008 Oct;9(8):738-84. doi: 10.2174/138920008786049302. Curr Drug Metab. 2008. PMID: 18855611 Review.
-
Genetic polymorphism of drug metabolising enzymes in African populations: implications for the use of neuroleptics and antidepressants.Brain Res Bull. 1997;44(5):561-71. doi: 10.1016/s0361-9230(97)00307-9. Brain Res Bull. 1997. PMID: 9365799 Review.
-
Similarity in recombination rate and linkage disequilibrium at CYP2C and CYP2D cytochrome P450 gene regions among Europeans indicates signs of selection and no advantage of using tagSNPs in population isolates.Pharmacogenet Genomics. 2012 Dec;22(12):846-57. doi: 10.1097/FPC.0b013e32835a3a6d. Pharmacogenet Genomics. 2012. PMID: 23089684
-
Global pharmacogenomics: Impact of population diversity on the distribution of polymorphisms in the CYP2C cluster among Brazilians.Pharmacogenomics J. 2012 Jun;12(3):267-76. doi: 10.1038/tpj.2010.89. Epub 2010 Dec 21. Pharmacogenomics J. 2012. PMID: 21173785
Cited by
-
Pharmacogenetics of ugt genes in North African populations.Pharmacogenomics J. 2018 Sep;18(5):609-612. doi: 10.1038/s41397-018-0034-4. Epub 2018 Jul 31. Pharmacogenomics J. 2018. PMID: 30061569 Free PMC article. No abstract available.
-
Variation in NAT2 acetylation phenotypes is associated with differences in food-producing subsistence modes and ecoregions in Africa.BMC Evol Biol. 2015 Dec 1;15:263. doi: 10.1186/s12862-015-0543-6. BMC Evol Biol. 2015. PMID: 26620671 Free PMC article.
-
Validation of PHASE for deriving N-acetyltransferase 2 haplotypes in the Western Cape mixed ancestry population.Afr J Lab Med. 2020 Dec 17;9(1):988. doi: 10.4102/ajlm.v9i1.988. eCollection 2020. Afr J Lab Med. 2020. PMID: 33392048 Free PMC article.
-
Pharmacokinetics of Tamoxifen and Its Major Metabolites and the Effect of the African Ancestry Specific CYP2D6*17 Variant on the Formation of the Active Metabolite, Endoxifen.J Pers Med. 2023 Jan 31;13(2):272. doi: 10.3390/jpm13020272. J Pers Med. 2023. PMID: 36836506 Free PMC article.
-
Functional Measurement of CYP2C9 and CYP3A4 Allelic Polymorphism on Sildenafil Metabolism.Drug Des Devel Ther. 2020 Nov 24;14:5129-5141. doi: 10.2147/DDDT.S268796. eCollection 2020. Drug Des Devel Ther. 2020. PMID: 33262574 Free PMC article.
References
-
- Wijnen PA, Op den Buijsch RA, Drent M. et al.Review article: The prevalence and clinical relevance of cytochrome P450 polymorphisms. Aliment Pharmacol Ther. 2007;26(Suppl 2):211–219. - PubMed
-
- Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther. 1994;270:414–423. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources